Unicycive Therapeutics (UNCY) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Unicycive Therapeutics (UNCY) is Moderate Underperform.

The composite score behind that read is -0.27, weighing +0.00 of bullish evidence against -0.26 bearish.

Unicycive Therapeutics last closed at $4.23, +0.95% on the session.

Against the IVW growth benchmark the position is +0.34% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

17 graded predictions for UNCY so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Unicycive Therapeutics in the 12th percentile on return on equity, where 100 is best.

Unicycive Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $116.71M.

StockMap tracks Unicycive Therapeutics as the 270th largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite Unicycive Therapeutics ranks 253rd of 365 in the group, against a group median of -0.21.